Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178163 | 0.79 | — | — | |
| SCHEMBL164659 | 0.75 | TSHR (0.42) | TSHRPNMTCYP1A2CYP2A6LMNA | |
| Hydrochloric Acid SCHEMBL1445738 | 0.75 | TSHR (0.42) | TSHRPNMTCYP1A2CYP2A6LMNA | |
| Bromide SCHEMBL1446266 | 0.75 | TSHR (0.42) | TSHRPNMTCYP1A2CYP2A6LMNA | |
| SCHEMBL23239 | 0.71 | — | — | |
| SCHEMBL3991309 | 0.71 | TSHR (0.61) | TSHRPNMTCYP1A2CYP2A6LMNA | |
| Fluoride SCHEMBL28376896 | 0.68 | TSHR (0.58) | TSHRPNMTCYP1A2CYP2A6LMNA | |
| SCHEMBL171713 | 0.68 | — | — | |
| SCHEMBL1395277 | 0.68 | TSHR (0.58) | TSHRPNMTCYP1A2CYP2A6LMNA | |
| Phosphine SCHEMBL22230521 | 0.68 | TSHR (0.58) | TSHRPNMTCYP1A2CYP2A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| EP-2120938-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008085302-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-0800520-B1 | PROCESS FOR THE PREPARATION OF LAMOTRIGINE | WELLCOME FOUND (GB) | 2002-06-19 | — | — | EP | disclosed |
| US-5925755-A | TREATING 2,3-DICHLOROPHENYLGLYOXYLIC ACID (FROM OXIDATION OF 2,3-DICHLOROACETOPHENONE) WITH THIOSEMICARBAZIDE YIELDS 6-(2,3-DICHLOROPHENYL)-5-OXO-3-THIO-1,2,4-TRIAZINE WHICH CAN BE AMINATED, CHLORINATED AND METHYLATED | GLAXO WELLCOME INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5912345-A | CHEMICAL CONDENSATION WITH CYCLIZATION AFTER TREATMENT WITH ULTRAVIOLET OR VISIBLE RADIATION | GLAXO WELLCOME INC. (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0800520-A1 | PROCESS FOR THE PREPARATION OF LAMOTRIGINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-15 | — | — | EP | disclosed |
| EP-0800521-A1 | PROCESS FOR THE PREPARATION OF LAMOTRIGINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020935-A1 | PROCESS FOR THE PREPARATION OF LAMOTRIGINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020934-A1 | PROCESS FOR THE PREPARATION OF LAMOTRIGINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | TSHR 638/4885PNMT 1779/4885CYP1A2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.